Breaking News Instant updates and real-time market news.

NFLX

Netflix

$309.25

5.58 (1.84%)

06:21
04/13/18
04/13
06:21
04/13/18
06:21

Netflix price target raised to $345 from $285 at Wells Fargo

Wells Fargo analyst Ken Sena raised his price target for Netflix to $345 from $285 saying his survey of 500 U.S. residents reaffirms the streaming service's pricing power. The survey indicates that based on the level and quality of content Netflix has today, 50% of respondents would pay a higher, and in some instances a much higher, price, Sena tells investors in a research note. The analyst modestly increased his outer-year estimates for Netflix and keeps an Outperform rating on the shares.

  • 16

    Apr

NFLX Netflix
$309.25

5.58 (1.84%)

04/12/18
UBSW
04/12/18
NO CHANGE
Target $345
UBSW
Buy
Netflix could see upside to Q1 subscription guidance, says UBS
UBS analyst Eric Sheridan believes Netflix could report upside to its Q1 subscription guidance when the company reports next Monday. He said his analysis points to broad-based growth trends across regions into 2018 with older markets continuing to mature but while sustaining solid levels. Sheridan reiterated his Buy rating and $345 price target on Netflix shares.
04/12/18
WEDB
04/12/18
NO CHANGE
Target $110
WEDB
Underperform
Material long-term risks remain for Netflix, says Wedbush
Wedbush analyst Michael Pachter expects Netflix to burn cash to fund content acquisition for many years, notwithstanding the fact that it has increased price three times while cash burn continues to grow. International profits may remain elusive due to competition for content and subs, and the price increases could cause a deceleration in subscriber growth, the analyst contends, adding that a negative free cash flow makes DCF valuation impossible. He reiterates an Underperform rating and $110 price target on the shares.
04/12/18
KEYB
04/12/18
NO CHANGE
Target $300
KEYB
Overweight
Growing spending should drive upside to Netflix Q1 subscriber estimates, says KeyBanc
KeyBanc analyst Andy Hargreaves says that an analysis of Netflix's ability to drive subscriber growth through marketing and content spending suggests the potential for upside to our subscriber estimates in Q1 and 2018, and suggests a business with substantial profit potential and growing barriers to entry. The analyst reiterates an Overweight rating and $300 price target on the shares.
04/13/18
DBAB
04/13/18
UPGRADE
DBAB
Buy
Netflix upgraded to Buy from Hold at Deutsche Bank

TODAY'S FREE FLY STORIES

MDR

McDermott

$6.08

0.28 (4.83%)

06:58
09/17/19
09/17
06:58
09/17/19
06:58
Hot Stocks
McDermott joint venture awarded module fabrication contract »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

AEE

Ameren

$77.17

0.58 (0.76%)

06:57
09/17/19
09/17
06:57
09/17/19
06:57
Upgrade
Ameren rating change  »

Ameren upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 10

    Nov

MCFT

MasterCraft Boat Holdings

$14.41

-0.1 (-0.69%)

06:55
09/17/19
09/17
06:55
09/17/19
06:55
Conference/Events
MasterCraft Boat Holdings to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

OSMT

Osmotica Pharmaceuticals

$3.84

0.15 (4.07%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Hot Stocks
Osmotica subsidiary submits NDA to FDA for RVL-1201 »

Vertical Pharmaceuticals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAST

Eastside Distilling

$4.97

-0.03 (-0.60%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Conference/Events
Eastside Distilling to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

, SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Alliance Data signs agreement to provide credit card services for Sally Beauty »

Alliance Data (ADS) has…

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

KAMN

Kaman

$63.22

0.55 (0.88%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Kaman awarded $42M order of Joint Programmable Fuzes »

Kaman announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYME

Zymeworks

$25.84

0.19 (0.74%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Zymeworks names Lota Zoth as board Chair, voluntarily delists from TSX »

Zymeworks announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

, ADS

Alliance Data

$132.88

-1.11 (-0.83%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Sally Beauty signs agreement with Alliance Data's card services business »

Sally Beauty Holdings…

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

MRK

Merck

$82.01

-0.6 (-0.73%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Merck: FDA accepts BLA, grants priority review for investigational Ebola vaccine »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

XLRN

Acceleron

$44.67

0.75 (1.71%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Recommendations
Acceleron analyst commentary  »

Acceleron should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGOV

NIC Inc.

$21.79

0.05 (0.23%)

06:40
09/17/19
09/17
06:40
09/17/19
06:40
Downgrade
NIC Inc. rating change  »

NIC Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPLK

Splunk

$114.87

1.19 (1.05%)

06:39
09/17/19
09/17
06:39
09/17/19
06:39
Upgrade
JPMorgan upgrades Splunk to Overweight after 19% selloff since late July »

JPMorgan analyst Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OLN

Olin

$19.27

0.46 (2.45%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Conference/Events
Olin management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$30.13

-0.77 (-2.49%)

06:37
09/17/19
09/17
06:37
09/17/19
06:37
Initiation
Axonics initiated  »

Axonics initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXGBY

Hexagon AB

$0.00

(0.00%)

06:36
09/17/19
09/17
06:36
09/17/19
06:36
Conference/Events
Hexagon AB management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Earnings
Apogee Enterprises reaffirms FY20 EPS view $3.00-$3.20, consensus $3.05 »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

MDGL

Madrigal Pharmaceuticals

$99.50

4.89 (5.17%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, UBER

Uber

$34.42

1.18 (3.55%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Periodicals
SoftBank backers consider slashing committments to Vision Fund, Bloomberg says »

The biggest backers of…

SFTBF

SoftBank

$0.00

(0.00%)

UBER

Uber

$34.42

1.18 (3.55%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSI

Stage Stores

$0.85

0.0298 (3.63%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Hot Stocks
Stage Stores announces plans to convert substantially all stores to off-price »

Stage Stores announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:31
09/17/19
09/17
06:31
09/17/19
06:31
Earnings
Apogee Enterprises reports Q2 EPS 72, consensus 64c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

IAC

IAC

$229.23

1.71 (0.75%)

06:30
09/17/19
09/17
06:30
09/17/19
06:30
Initiation
IAC initiated  »

IAC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

AMRN

Amarin

$17.26

0.55 (3.29%)

, MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

06:29
09/17/19
09/17
06:29
09/17/19
06:29
Recommendations
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list »

Citi analyst Joel Beatty…

AMRN

Amarin

$17.26

0.55 (3.29%)

MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

NERV

Minerva

$8.12

0.12 (1.50%)

SRPT

Sarepta

$87.02

1.01 (1.17%)

ELOX

Eloxx Pharmaceuticals

$6.45

0.1 (1.57%)

NGM

NGM Biopharmaceuticals

$15.85

-0.15 (-0.94%)

PTCT

PTC Therapeutics

$42.99

0.16 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.